

# Advances in Delivery Science and Technology

**Series editor**

Michael J. Rathbone

More information about this series at <http://www.springer.com/series/8875>

Ali R. Rajabi-Siahboomi  
Editor

# Multiparticulate Drug Delivery

Formulation, Processing and Manufacturing

 Springer

*Editor*

Ali R. Rajabi-Siahboomi  
VP & Chief Scientific Officer, Colorcon Inc.  
Harleysville, PA, USA

ISSN 2192-6204 ISSN 2192-6212 (electronic)  
Advances in Delivery Science and Technology  
ISBN 978-1-4939-7010-0 ISBN 978-1-4939-7012-4 (eBook)  
DOI 10.1007/978-1-4939-7012-4

Library of Congress Control Number: 2017937366

© Controlled Release Society 2017

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by Springer Nature  
The registered company is Springer Science+Business Media LLC  
The registered company address is: 233 Spring Street, New York, NY 10013, U.S.A.

*I dedicate this book to my parents who despite their lack of formal education, inspired me to learn and share my learning, even though it meant that we did not see each other for many years; to my lovely wife, Angela; and sons, Jonathan and Anthony, for their support and inspiration to always do my best.*

# Preface

Multiparticulate drug delivery systems are widely used in the pharmaceutical industry due to their formulation flexibility for the manufacturers and clinical benefits that they offer to the patients. Although the introduction and use of this platform technology dates back to 1950s (under the concept of Spansules by SmithKline and French), there is still a significant level of interest to leverage multiparticulates for achieving various release profiles and for special age groups like pediatric and elderly patients. Multiparticulate systems are developed in a wide range of sizes, i.e., as small as 150  $\mu\text{m}$  or as large as 2–3 mm in diameter and offer superior clinical and technical advantages over many other specialized drug delivery technologies. Due to their multiplicity of units and small sizes, they exhibit reduced risk of dose dumping, spread along the gastro-intestinal tract (GIT), when taken orally, and therefore, offer specific biopharmaceutics advantages over the larger single units. Their transit time through different segments of the GIT is more predictable, reducing inter- and intra-subject variability. Multiparticulates possess large surface area for drug release and when dispersed along the gut, maximize drug absorption without possible local irritation in the GIT.

There is a widespread availability of machinery suitable for the development and manufacture of multiparticulates in the pharmaceutical industry, which is another driving factor for popularity of this drug delivery technology. Most pharmaceutical companies have small- to large-scale fluid bed technology with various setup options to handle multiparticulates and, therefore, enable development of desired formulations using various design approaches with polymers in aqueous or solvent-based systems. In addition, there is a wealth of knowledge and know-how around this technology in the literature, among suppliers of raw materials, polymers, and machine manufacturers serving formulation scientists achieve their desired formulation design and finish drug products. This book is an accumulation of experiences, thoughts, and best practices offered by leading experts from academia, users, and manufacturers. It is complementary to *Multiparticulate Oral Drug Delivery*, a book edited by Isaac Ghebre-Sellassie and published by Marcel Dekker, Inc. in 1994, with a view to update some of the content and add recent advances related to the

technology. This book is intended for scientists who are new or already familiar with the multiparticulate technology, whether in the academia or in the industry. It is based on science and practice which provides the readers with knowledge of various choices available to formulate, scale-up, and test the quality and performance of multiparticulates.

The manufacture of inert starter seeds, mainly based on sugar spheres and their functionally related characteristics, has been discussed in Chap. 2. These starter seeds are then used for drug layering and further processing based on target release profiles. Alternative methods for the development and manufacture of multiparticulates such as extrusion-spheronization, mini-tabs, and microencapsulation where drug is included in the core of the multiparticulates are discussed in Chaps. 3, 5, and 6, respectively. Majority of processing of multiparticulates are carried out using a fluid bed machine, and the late David Jones, who was the undisputed subject matter expert in this area, described the fundamentals of fluid bed technology with special emphasis on process robustness and scale-up in Chap. 4. Polymers are generally used to coat the drug bearing multiparticulates in order to modulate the release of the drug. The most commonly used functional polymers for these purposes: poly(meth)acrylate copolymers and ethylcellulose have been described, with specific case studies for their unique applications, in Chaps. 10 and 11, respectively. In most cases, multiparticulates are filled into hard shell capsules as described in Chap. 13 or on occasions, they are compressed into tablets. In recent years, there has been a major interest in special applications of multiparticulates for fixed dose combinations and pediatric formulations, and Chaps. 7 and 9 cover these important topics. Chapters 8, 12, and 14 discuss at length the characterization of multiparticulates. While Chap. 12 describes various ways for in-line characterization of multiparticulates, Chap. 8 discusses the dissolution testing of the final formulation and how to relate these data to *in vivo* performance (Chap. 14).

I would like to express my special thanks to all contributors who allocated their time and effort to prepare their respective chapters, review the others, and help me bring this book to completion.

Harleysville, PA, USA

Ali R. Rajabi-Siahboomi

# Contents

<b>1</b>	<b>Overview of Multiparticulate Systems for Oral Drug Delivery . . . .</b>	<b>1</b>
	Ali R. Rajabi-Siahboomi	
<b>2</b>	<b>Characterization of Inert Cores for Multiparticulate Dosage Forms . . . . .</b>	<b>5</b>
	Richard Sidwell, Jason Hansell, Manish Rane, and Ali R. Rajabi-Siahboomi	
<b>3</b>	<b>The Science and Practice of Extrusion-Spheronization . . . . .</b>	<b>37</b>
	Markus Thommes and Peter Kleinebudde	
<b>4</b>	<b>Fluid Bed Technology, Process Robustness, and Scale-Up . . . . .</b>	<b>65</b>
	David M. Jones and Ali R. Rajabi-Siahboomi	
<b>5</b>	<b>Mini-tabs: Versatile Multiparticulate Option for Oral Drug Delivery . . . . .</b>	<b>95</b>
	Marina Levina, Hue Voung, and Ali R. Rajabi-Siahboomi	
<b>6</b>	<b>Science and Practice of Microencapsulation Technology . . . . .</b>	<b>119</b>
	Sandile M.M. Khamanga and Roderick B. Walker	
<b>7</b>	<b>Multiparticulate Technologies for Fixed-Dose Combinations . . . . .</b>	<b>155</b>
	W. Brett Caldwell and Aditya M. Kaushal	
<b>8</b>	<b>Dissolution Test Considerations for Oral Multiparticulate Systems . . . . .</b>	<b>169</b>
	Sandra Klein	
<b>9</b>	<b>Multiparticulate Systems for Paediatric Drug Delivery . . . . .</b>	<b>213</b>
	Affiong Iyire and Afzal R. Mohammed	

<b>10 Application of Poly(meth)acrylate Copolymers for Oral Multiparticulate Drug Delivery Systems . . . . .</b>	<b>237</b>
Theresia Kuntz, Wolfgang Weisbrod, Subhashis Chakraborty, and Brigitte Skalsky	
<b>11 Ethylcellulose Applications in Multiparticulate Systems . . . . .</b>	<b>267</b>
Ali R. Rajabi-Siahboomi, Raxit Y. Mehta, Vaibhav Ambudkar, Viana Dias, and Sandip Tiwari	
<b>12 In-Line Particle Size Characterization of Multiparticulate Systems . . . . .</b>	<b>301</b>
Stefan Dietrich and Dieter Petrak	
<b>13 Filling of Hard Shell Capsules and Packaging Aspects of Multiparticulate Systems . . . . .</b>	<b>333</b>
Guia Bertuzzi and Stefania Barzanti	
<b>14 <i>In Vivo</i> Characterization of Oral Multiparticulate Systems . . . . .</b>	<b>359</b>
Lee Ann Hodges	
<b>Index . . . . .</b>	<b>387</b>



# Contributors

**Vaibhav Ambudkar** Colorcon Inc., Harleysville, PA, USA

**Stefania Barzanti** IMA S.p.A, Bologna, Italy

**Guia Bertuzzi** IMA S.p.A, Bologna, Italy

**W. Brett Caldwell** Bend Research Inc., A Division of Capsugel, Research Road, Bend, OR, USA

**Subhashis Chakraborty** Evonik India Pvt. Ltd., Mumbai, India

**Viena Dias** Indoco Remedies Ltd., Verna, Goa, India

**Stefan Dietrich** Parsum GmbH, Chemnitz, Germany

**Jason Hansell** Colorcon Inc., Harleysville, PA, USA

**Lee Ann Hodges** Quintiles Malaysia Sdn Bhd, Kuala Lumpur, Malaysia

**Affiong Iyire** Aston School of Pharmacy, Aston University, Birmingham, UK

**David M. Jones** OWI – Consulting Inc., Coatesville, PA, USA

**Aditya M. Kaushal** Bend Research Inc., A Division of Capsugel, Research Road, Bend, OR, USA

**Sandile M.M. Khamanga** Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa

**Sandra Klein** University of Greifswald, Department of Pharmacy, Institute of Biopharmaceutics and Pharmaceutical Technology, Center of Drug Absorption and Transport (C\_DAT), Greifswald, Germany

**Peter Kleinebudde** Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-University, Duesseldorf, Germany

**Theresa Kuntz** Evonik Nutrition & Care GmbH, Kirschenallee, Darmstadt, Germany

**Marina Levina** GSK, Ware, UK

**Raxit Y. Mehta** Colorcon Inc., Harleysville, PA, USA

**Afzal R. Mohammed** Aston School of Pharmacy, Aston University, Birmingham, UK

**Dieter Petrak** Chemnitz University of Technology, Chemnitz, Germany

**Ali R. Rajabi-Siahboomi** Colorcon, Inc., Harleysville, PA, USA

**Manish Rane** Colorcon Inc., Harleysville, PA, USA

**Richard Sidwell** Recro Pharma Inc., Gainesville, PA, USA

**Brigitte Skalsky** Evonik Nutrition & Care GmbH, Kirschenallee, Darmstadt, Germany

**Markus Thommes** Chair of Solids Process Engineering. Technical University Dortmund, Germany

**Sandip Tiwari** Teva Pharmaceutical Industries Ltd. (Actavis), Fort Lauderdale, FL, USA

**Hue Young** Colorcon Ltd, Flagship House, Dartford, UK

**Roderick B. Walker** Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa

**Wolfgang Weisbrod** Evonik Nutrition & Care GmbH, Kirschenallee, Darmstadt, Germany